JP2001509780A - 緑内障および眼虚血の治療のための特定のイソキノリンスルホニル化合物の使用 - Google Patents
緑内障および眼虚血の治療のための特定のイソキノリンスルホニル化合物の使用Info
- Publication number
- JP2001509780A JP2001509780A JP52379397A JP52379397A JP2001509780A JP 2001509780 A JP2001509780 A JP 2001509780A JP 52379397 A JP52379397 A JP 52379397A JP 52379397 A JP52379397 A JP 52379397A JP 2001509780 A JP2001509780 A JP 2001509780A
- Authority
- JP
- Japan
- Prior art keywords
- composition
- group
- compound
- weight
- carbon atoms
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.治療に有効な量の以下の式の化合物、およびその薬学的に受容可能な塩;な らびにそのための眼科的に受容可能なキャリアーを含む、緑内障、眼高血圧、眼 虚血、および関連疾病の処置のための眼科組成物: ここでR=HまたはOH。 2.前記組成物が局所的な眼科組成物である、請求項1に記載の組成物。 3.R=Hである、請求項2に記載の組成物。 4.前記化合物の最終組成物濃度が約0.001〜約10.0重量%の間である、請求項 3に記載の組成物。 5.前記化合物の最終組成物濃度が約0.01〜約3.0重量%の間であり、かつその 薬学的に受容可能な塩が塩酸塩である、請求項4に記載の組成物。 6. 前記化合物の最終組成物濃度が約0.1〜約2.0重量%の間である、請求項5 に記載の組成物。 7.前記組成物が、アニオン性粘膜擬態物ポリマーおよび細分割薬物キャリアー 基質からなる群より選択される少なくとも1つの成分をさらに含む局所的組成物 である、請求項1に記載の組成物。 8.前記化合物の最終組成物濃度が約0.001〜約10.0重量%の間であり;アニオ ン性粘膜擬態物ポリマーおよび細分割薬物キャリアー基質の両方が存在し;該粘 膜擬態物ポリマーの最終組成物濃度が約0.05〜約8.0重量%の間であり;かつ、 該細分割薬物キャリアー基質の最終組成物濃度が約0.05〜約10.0重量%の間であ る、請求項7の組成物。 9.前記組成物が、ゲル化ポリサッカライドおよび細分割薬物キャリアー基質か らなる群より選択される少なくとも1つの成分をさらに含む局所的組成物である 、請求項1に記載の組成物。 10.前記化合物の最終組成物濃度が約0.001〜約10.0重量%の間であり;ゲル 化ポリサッカライドおよび細分割薬物キャリアー基質の両方が存在し;該ゲル化 ポリサッカライドの最終組成物濃度が約0.1〜約3.0重量%の間であり;かつ、該 細分割薬物キャリアー基質の最終組成物濃度が約0.05〜約10.0重量%の間である 、請求項9の組成物。 11.眼科的に有効な量の以下の式の化合物およびその薬学的に受容可能な塩; ならびにそのための眼科的に受容可能なキャリアーを含む組成物を患者に投与す る工程を包含する、緑内障、眼高血圧、眼虚血、および関連疾病などのような症 状のうち1つ以上を有する患者の緑内障、眼高血圧、眼虚血、および関連疾病を 処置する方法: ここで、R1は水素原子、塩素原子または水酸基を表し;そしてR1が水素原子を表 す場合、 Aは、非置換もしくは1〜6個の炭素原子を有するアルキル基で置換されたエ チレン基、フェニル基またはベンジル基を表し、 R2およびR3は、互いに直接結合し、それにより非置換もしくは1〜6個の炭素 原子を有するアルキル基で置換されたトリメチレン基、フェニル基またはベンジ ル基を形成し、そして R4は、水素原子または1〜6個の炭素原子を有するアルキル基を表し;そして R1が塩素原子または水酸基を表す場合、 Aは、2〜6個の炭素原子を有するアルキレン基を表し、該基は、非置換もし くは1〜6個の炭素原子を有するアルキル基で置換され、 R2およびR3は、互いに結合しておらず、それぞれ独立に水素原子または1〜6 個の炭素原子を有するアルキル基を表し、あるいはR2およびR3は互いに結合し、 それにより非置換もしくは1〜6個の炭素原子を有するアルキル基で置換された エチレン基、または非置換もしくは1〜6個の炭素原子を有するアルキル基で置 換されたトリメチレン基を形成し、そして R4は、水素原子、1〜6個の炭素原子を有するアルキル基またはアミジノ基を 表す。 12.眼科的に有効な量の以下の式の化合物およびその薬学的に受容可能な塩を 含む組成物を患者に投与する工程を包含する、緑内障、眼高血圧、眼虚血、およ び関連疾病などのような症状のうち1つ以上を有する患者の緑内障、眼高血圧、 眼虚血、および関連疾病を処置する方法: ここでR=HまたはOH。 13.前記化合物の投与が局所的に行われる、請求項12に記載の方法。 14.R=Hである、請求項12に記載の方法。 15.前記化合物の最終組成物濃度が約0.001〜約10.0重量%の間である、請求 項14に記載の方法。 16.前記化合物の最終組成物濃度が約0.01〜約3.0重量%の間である、請求項 15に記載の方法。 17.前記化合物の最終組成物濃度が約0.1〜約2.0重量%の間であり、かつその 薬学的に受容可能な塩が塩酸塩である、請求項16に記載の方法。 18.前記組成物が持続性の放出成分をさらに含む、請求項12に記載の方法。 19.前記持続性の放出成分が、粘膜擬態物ポリマー、ゲル化ポリサッカライド 、細分割薬物キャリアー基質、およびその組み合わせからなる群から選択される 、請求項18に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US935195P | 1995-12-21 | 1995-12-21 | |
US60/009,351 | 1995-12-21 | ||
PCT/US1996/020197 WO1997023222A1 (en) | 1995-12-21 | 1996-12-20 | Use of certain isoquinolinesulfonyl compounds for the treatment of glaucoma and ocular ischemia |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2001509780A true JP2001509780A (ja) | 2001-07-24 |
JP3719609B2 JP3719609B2 (ja) | 2005-11-24 |
Family
ID=21737108
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP52379397A Expired - Fee Related JP3719609B2 (ja) | 1995-12-21 | 1996-12-20 | 緑内障および眼虚血の治療のための特定のイソキノリンスルホニル化合物の使用 |
Country Status (14)
Country | Link |
---|---|
US (2) | US6271224B1 (ja) |
EP (1) | EP0868186B1 (ja) |
JP (1) | JP3719609B2 (ja) |
KR (1) | KR100452715B1 (ja) |
CN (1) | CN1155383C (ja) |
AT (1) | ATE289815T1 (ja) |
AU (1) | AU720326B2 (ja) |
DE (1) | DE69634414T2 (ja) |
ES (1) | ES2238702T3 (ja) |
HK (1) | HK1015691A1 (ja) |
MX (1) | MX9805033A (ja) |
PT (1) | PT868186E (ja) |
TW (1) | TW534814B (ja) |
WO (1) | WO1997023222A1 (ja) |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005514429A (ja) * | 2001-12-21 | 2005-05-19 | アルコン、インコーポレイテッド | 眼/耳用薬物のキャリヤーとしての合成無機質ナノ粒子の使用 |
JP2005514433A (ja) * | 2001-12-21 | 2005-05-19 | アルコン、インコーポレイテッド | 眼/耳用医薬組成物の粘性及び他の物理的性質の改質の為の無機質ナノ粒子の使用 |
WO2006068208A1 (ja) * | 2004-12-23 | 2006-06-29 | Kowa Co., Ltd. | 緑内障予防又は治療剤 |
WO2007026664A1 (ja) * | 2005-08-30 | 2007-03-08 | Asahi Kasei Pharma Corporation | スルホンアミド化合物 |
WO2008105058A1 (ja) * | 2007-02-27 | 2008-09-04 | Asahi Kasei Pharma Corporation | スルホンアミド化合物 |
JP2009298808A (ja) * | 2002-08-29 | 2009-12-24 | Santen Pharmaceut Co Ltd | Rhoキナーゼ阻害剤とプロスタグランジン類からなる緑内障治療剤 |
US7964613B2 (en) | 2007-02-28 | 2011-06-21 | Asahi Kasei Pharma Corporation | Sulfonamide compound |
US7972612B2 (en) | 2002-11-18 | 2011-07-05 | Santen Pharmaceutical Co., Ltd. | Remedy for glaucoma comprising Rho kinase inhibitor and β-blocker |
US8232292B2 (en) | 2007-07-02 | 2012-07-31 | Asahi Kasei Pharma Corporation | Sulfonamide compound and crystal thereof |
JP2013035802A (ja) * | 2011-08-10 | 2013-02-21 | D Western Therapeutics Institute Inc | 緑内障又は高眼圧症の予防又は治療剤 |
JP2013129605A (ja) * | 2011-12-20 | 2013-07-04 | Kowa Co | 緑内障治療薬を含有する安定なフィルム製剤 |
JP2013129604A (ja) * | 2011-12-20 | 2013-07-04 | Kowa Co | 緑内障治療薬を含有する徐放性フィルム製剤 |
JP5557408B1 (ja) * | 2013-04-24 | 2014-07-23 | 国立大学法人九州大学 | 眼底疾患治療剤 |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100444843C (zh) * | 1998-08-10 | 2008-12-24 | 旭化成制药株式会社 | 法舒地尔盐酸盐缓释口服制剂 |
EP1459742B9 (en) | 1998-08-17 | 2012-05-02 | Senju Pharmaceutical Co., Ltd. | Agent for prophylaxis and treatment of asthenopia and pseudomyopia |
WO2000057914A1 (fr) * | 1999-03-25 | 2000-10-05 | Santen Pharmaceutical Co., Ltd. | Agents permettant d'abaisser la tension oculaire |
ATE506967T1 (de) | 1999-04-27 | 2011-05-15 | Mitsubishi Tanabe Pharma Corp | Arzneimittel zur präventiven oder therapeutische behandlung von lebererkrankungen |
EP1064944A1 (en) * | 1999-06-25 | 2001-01-03 | Schering Aktiengesellschaft | Protein kinase N inhibitor comprising Fasudil |
US7109208B2 (en) | 2001-04-11 | 2006-09-19 | Senju Pharmaceutical Co., Ltd. | Visual function disorder improving agents |
EP1550446A1 (en) * | 2003-11-14 | 2005-07-06 | Switch Biotech Aktiengesellschaft | Use of 1-(5-isoquinolinesulfonyl) homopiperazine for treating and preventing hypopigmentary disorders |
WO2004096222A1 (en) * | 2003-04-30 | 2004-11-11 | Switch Biotech Ag | Use of 1-(5-isoquinolinesulfonyl)homopiperazine, its active metabolites, isomers and salts for treating and preventing hypopigmentary disorders |
JP4110324B2 (ja) | 2003-10-15 | 2008-07-02 | 宇部興産株式会社 | 新規インダゾール誘導体 |
MXPA06006862A (es) * | 2003-12-22 | 2007-01-26 | Alcon Inc | Agentes para el tratamiento de la retinopatia diabetica y formacion de drusen en degeneracion macular. |
TW200526224A (en) * | 2003-12-22 | 2005-08-16 | Alcon Inc | Short form c-Maf transcription factor antagonists for treatment of glaucoma |
AU2004308919B2 (en) * | 2003-12-22 | 2009-11-12 | Alcon, Inc. | Agents for treatment of glaucomatous retinopathy and optic neuropathy |
JP4789264B2 (ja) | 2004-03-16 | 2011-10-12 | 旭化成ファーマ株式会社 | ファスジル含有製剤及びその安定性を改善する方法 |
US20060115870A1 (en) * | 2004-03-30 | 2006-06-01 | Alcon, Inc. | High throughput assay for human Rho kinase activity |
WO2005102345A1 (en) * | 2004-03-30 | 2005-11-03 | Alcon, Inc. | Use of rho kinase inhibitors in the treatment of hearing loss, tinnitus and improving body balance |
US20080096238A1 (en) * | 2004-03-30 | 2008-04-24 | Alcon, Inc. | High throughput assay for human rho kinase activity with enhanced signal-to-noise ratio |
US20060142270A1 (en) * | 2004-12-23 | 2006-06-29 | Kowa Co., Ltd. | Preventing or treating agent for glaucoma |
EP1830853B1 (en) * | 2004-12-27 | 2011-08-10 | Novartis AG | Aminopyrazine analogs for treating glaucoma and other rho kinase-mediated diseases |
KR101333970B1 (ko) | 2005-05-19 | 2013-11-27 | 코와 가부시키가이샤 | 녹내장 예방 또는 치료제 |
CN100367967C (zh) * | 2005-12-12 | 2008-02-13 | 天津红日药业股份有限公司 | 一种盐酸法舒地尔口服制剂 |
US7867999B1 (en) | 2005-12-22 | 2011-01-11 | Alcon Research, Ltd. | Hydroxyamino- and amino-substituted pyridine analogs for treating rho kinase-mediated diseases and conditions |
CA2629342A1 (en) * | 2005-12-22 | 2007-07-05 | Alcon Research, Ltd. | (indazol-5-yl)-pyrazines and (1,3-dihydro-indol-2-one)- pyrazines for treating rho kinase-mediated diseases and conditions |
US8227480B2 (en) | 2006-06-08 | 2012-07-24 | Ube Industries, Ltd. | Indazole derivative having spiro ring structure in side chain |
US20080064681A1 (en) * | 2006-09-11 | 2008-03-13 | Hiroyoshi Hidaka | Therapeutic agent for treating glaucoma |
AR064420A1 (es) * | 2006-12-21 | 2009-04-01 | Alcon Mfg Ltd | Composiciones farmaceuticas oftalmicas que comprenden una cantidad efectiva de analogos de 6-aminoimidazo[1,2b]piridazinas, utiles para el tratamiento del glaucoma y/o controlar la presion intraocular normal o elevada(iop). |
US20120101167A1 (en) * | 2010-10-25 | 2012-04-26 | Langham Maurice E | Treatment of ocular and cerebral ischemia |
CN102028694B (zh) * | 2010-11-12 | 2012-03-14 | 天津红日药业股份有限公司 | 法舒地尔经眼部给药用于制备治疗青光眼药物中的应用 |
HUE029976T2 (en) | 2010-12-22 | 2017-04-28 | D Western Therapeutics Inst Inc | New substituted isoquinoline derivatives |
WO2012105674A1 (ja) | 2011-02-04 | 2012-08-09 | 興和株式会社 | 緑内障予防又は治療のための薬物療法 |
CN102138895B (zh) * | 2011-03-30 | 2013-01-23 | 天津红日药业股份有限公司 | 一种含盐酸法舒地尔的滴眼剂及其制备 |
US8980910B2 (en) * | 2011-04-01 | 2015-03-17 | Indiana University Research And Technology Corporation | Treatment of glaucoma |
EP2628482A1 (en) | 2012-02-17 | 2013-08-21 | Academisch Medisch Centrum | Rho kinase inhiitors for use in the treatment of neuroblastoma |
AU2016326750B2 (en) * | 2015-09-25 | 2022-09-15 | Okogen, Inc. | Viral conjunctivitis treatment using ranpirnase and/or amphinase |
US20180296474A1 (en) * | 2015-10-13 | 2018-10-18 | INSERM (Institut National de la Santé et de la Recherche Médicale | Methods and pharmaceutical compositions for the treatment of retinal capillary non-perfusion |
EP4088719A1 (en) * | 2015-10-13 | 2022-11-16 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods and pharmaceutical compositions for the treatment of retinal capillary non-perfusion |
AU2018369784B2 (en) | 2017-11-14 | 2023-06-01 | Massachusetts Eye And Ear Infirmary | RUNX1 inhibition for treatment of proliferative vitreoretinopathy and conditions associated with epithelial to mesenchymal transition |
WO2019124488A1 (ja) | 2017-12-21 | 2019-06-27 | 参天製薬株式会社 | セペタプロストとRhoキナーゼ阻害剤との組み合わせ医薬 |
CA3110661A1 (en) | 2018-08-29 | 2020-03-05 | University Of Massachusetts | Inhibition of protein kinases to treat friedreich ataxia |
AU2021331624A1 (en) * | 2020-08-31 | 2023-05-04 | Viewpoint Therapeutics, Inc. | Compounds and formulations for treating ophthalmic diseases |
US11918581B2 (en) | 2021-01-11 | 2024-03-05 | Incyte Corporation | Combination therapy comprising JAK pathway inhibitor and rock inhibitor |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4456757A (en) | 1981-03-20 | 1984-06-26 | Asahi Kasei Kogyo Kabushiki Kaisha | Isoquinolinesulfonyl derivatives and process for the preparation thereof |
NZ200429A (en) | 1981-04-30 | 1984-10-19 | Smith & Nephew Ass | Applicator for placing pharmaceutically active agent in contact with moist surface,e.g.,eye |
US4730013A (en) | 1981-10-08 | 1988-03-08 | Merck & Co., Inc. | Biosoluble ocular insert |
US4678783B1 (en) * | 1983-11-04 | 1995-04-04 | Asahi Chemical Ind | Substituted isoquinolinesulfonyl compounds |
US4911920A (en) | 1986-07-30 | 1990-03-27 | Alcon Laboratories, Inc. | Sustained release, comfort formulation for glaucoma therapy |
US5212162A (en) | 1991-03-27 | 1993-05-18 | Alcon Laboratories, Inc. | Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions |
AU4246793A (en) * | 1992-05-13 | 1993-12-13 | Alcon Laboratories, Inc. | Topical ophthalmic compositions comprising a combination of calcium antagonists with known antiglaucoma agents |
US5922773A (en) | 1992-12-04 | 1999-07-13 | The Children's Medical Center Corp. | Glaucoma treatment |
JP3683908B2 (ja) | 1993-10-13 | 2005-08-17 | アラーガン、インコーポレイテッド | (2−イミダゾリン−2−イルアミノ)キノキサリン誘導体の使用方法 |
EP0682664B1 (en) * | 1993-12-08 | 2001-03-14 | Alcon Laboratories, Inc. | Compounds having both potent calcium antagonist and antioxidant activity and use thereof as cytoprotective agents |
JP3805360B2 (ja) | 1994-01-24 | 2006-08-02 | アラーガン、インコーポレイテッド | α▲下2A▼アドレナリン受容体作動剤としての芳香族2−アミノ−イミダゾール誘導体 |
JPH07277979A (ja) | 1994-04-12 | 1995-10-24 | Asahi Chem Ind Co Ltd | 過粘性症候群治療または予防剤 |
US5602143A (en) | 1994-12-08 | 1997-02-11 | Allergan | Method for reducing intraocular pressure in the mammalian eye by administration of guanylate cyclase inhibitors |
US5573758A (en) | 1995-04-28 | 1996-11-12 | Allergan | Method for reducing intraocular pressure in the mammalian eye by administration of potassium channel blockers |
US5798380A (en) | 1996-02-21 | 1998-08-25 | Wisconsin Alumni Research Foundation | Cytoskeletal active agents for glaucoma therapy |
-
1996
- 1996-12-20 KR KR10-1998-0704649A patent/KR100452715B1/ko not_active IP Right Cessation
- 1996-12-20 WO PCT/US1996/020197 patent/WO1997023222A1/en active IP Right Grant
- 1996-12-20 ES ES96945220T patent/ES2238702T3/es not_active Expired - Lifetime
- 1996-12-20 CN CNB961996730A patent/CN1155383C/zh not_active Expired - Fee Related
- 1996-12-20 EP EP96945220A patent/EP0868186B1/en not_active Expired - Lifetime
- 1996-12-20 US US09/077,575 patent/US6271224B1/en not_active Expired - Fee Related
- 1996-12-20 AU AU14644/97A patent/AU720326B2/en not_active Ceased
- 1996-12-20 AT AT96945220T patent/ATE289815T1/de not_active IP Right Cessation
- 1996-12-20 DE DE69634414T patent/DE69634414T2/de not_active Expired - Fee Related
- 1996-12-20 PT PT96945220T patent/PT868186E/pt unknown
- 1996-12-20 JP JP52379397A patent/JP3719609B2/ja not_active Expired - Fee Related
-
1997
- 1997-02-04 TW TW086101346A patent/TW534814B/zh not_active IP Right Cessation
-
1998
- 1998-06-19 MX MX9805033A patent/MX9805033A/es not_active IP Right Cessation
-
1999
- 1999-02-27 HK HK99100710D patent/HK1015691A1/xx not_active IP Right Cessation
-
2001
- 2001-07-31 US US09/919,301 patent/US6403590B1/en not_active Expired - Fee Related
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005514433A (ja) * | 2001-12-21 | 2005-05-19 | アルコン、インコーポレイテッド | 眼/耳用医薬組成物の粘性及び他の物理的性質の改質の為の無機質ナノ粒子の使用 |
JP2005514429A (ja) * | 2001-12-21 | 2005-05-19 | アルコン、インコーポレイテッド | 眼/耳用薬物のキャリヤーとしての合成無機質ナノ粒子の使用 |
JP2009298808A (ja) * | 2002-08-29 | 2009-12-24 | Santen Pharmaceut Co Ltd | Rhoキナーゼ阻害剤とプロスタグランジン類からなる緑内障治療剤 |
US7972612B2 (en) | 2002-11-18 | 2011-07-05 | Santen Pharmaceutical Co., Ltd. | Remedy for glaucoma comprising Rho kinase inhibitor and β-blocker |
WO2006068208A1 (ja) * | 2004-12-23 | 2006-06-29 | Kowa Co., Ltd. | 緑内障予防又は治療剤 |
EP1818059A4 (en) * | 2004-12-23 | 2007-12-26 | Kowa Co | PREVENTIVE OR THERAPEUTIC AGENT AGAINST GLAUKOM |
EA011085B1 (ru) * | 2004-12-23 | 2008-12-30 | Кова Ко., Лтд. | Средство для профилактики или лечения глаукомы |
WO2007026664A1 (ja) * | 2005-08-30 | 2007-03-08 | Asahi Kasei Pharma Corporation | スルホンアミド化合物 |
US8415372B2 (en) | 2007-02-27 | 2013-04-09 | Asahi Kasei Pharma Corporation | Sulfonamide compound |
WO2008105058A1 (ja) * | 2007-02-27 | 2008-09-04 | Asahi Kasei Pharma Corporation | スルホンアミド化合物 |
US7964613B2 (en) | 2007-02-28 | 2011-06-21 | Asahi Kasei Pharma Corporation | Sulfonamide compound |
US8232292B2 (en) | 2007-07-02 | 2012-07-31 | Asahi Kasei Pharma Corporation | Sulfonamide compound and crystal thereof |
US8664243B2 (en) | 2007-07-02 | 2014-03-04 | Asahi Kasei Pharma Corporation | Sulfonamide compound and crystal thereof |
JP2013035802A (ja) * | 2011-08-10 | 2013-02-21 | D Western Therapeutics Institute Inc | 緑内障又は高眼圧症の予防又は治療剤 |
JP2013129605A (ja) * | 2011-12-20 | 2013-07-04 | Kowa Co | 緑内障治療薬を含有する安定なフィルム製剤 |
JP2013129604A (ja) * | 2011-12-20 | 2013-07-04 | Kowa Co | 緑内障治療薬を含有する徐放性フィルム製剤 |
JP5557408B1 (ja) * | 2013-04-24 | 2014-07-23 | 国立大学法人九州大学 | 眼底疾患治療剤 |
Also Published As
Publication number | Publication date |
---|---|
WO1997023222A1 (en) | 1997-07-03 |
CN1207680A (zh) | 1999-02-10 |
KR19990076580A (ko) | 1999-10-15 |
TW534814B (en) | 2003-06-01 |
US6271224B1 (en) | 2001-08-07 |
ES2238702T3 (es) | 2005-09-01 |
PT868186E (pt) | 2005-05-31 |
DE69634414D1 (de) | 2005-04-07 |
AU1464497A (en) | 1997-07-17 |
CN1155383C (zh) | 2004-06-30 |
DE69634414T2 (de) | 2005-11-17 |
HK1015691A1 (en) | 1999-10-22 |
EP0868186B1 (en) | 2005-03-02 |
JP3719609B2 (ja) | 2005-11-24 |
US6403590B1 (en) | 2002-06-11 |
ATE289815T1 (de) | 2005-03-15 |
MX9805033A (es) | 1998-09-30 |
AU720326B2 (en) | 2000-05-25 |
EP0868186A1 (en) | 1998-10-07 |
KR100452715B1 (ko) | 2004-12-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3719609B2 (ja) | 緑内障および眼虚血の治療のための特定のイソキノリンスルホニル化合物の使用 | |
US6294553B1 (en) | Method for treating ocular pain | |
JPH08502485A (ja) | 緑内症(glaucoma)治療のための、プロスタグランジンとクロニジン誘導体の組合わせ | |
JPH07508030A (ja) | カルシウムアンタゴニストと公知の抗緑内障薬との組合せを含む眼局所用組成物 | |
US10688113B2 (en) | Methods of treating eye pain with aminophosphinic derivatives | |
US5438060A (en) | Method of reducing elevated intraocular pressure | |
AU704938B2 (en) | Combination therapy for treating glaucoma | |
EP0979652B1 (en) | Remedial composition for intraocular hypertension or glaucoma | |
CA2240271C (en) | Use of certain isoquinolinesulfonyl compounds for the treatment of glaucoma and ocular ischemia | |
US5308849A (en) | Method of reducing elevated intraocular pressure | |
EP0728480A1 (en) | Use of ifenprodil for treatment of elevated intraocular pressure | |
CA2356912C (en) | Pharmaceutical compositions for the treatment of ocular hypertension or glaucoma | |
EP0375299A1 (en) | Combinations of angiotensin converting enzyme, and carbonic anhydrase, inhibitors for treating glaucoma | |
TWI253345B (en) | Ophthalmic composition for the treatment of glaucoma, ocular hypertension, ocular ischemia and related disorders | |
JPH02504150A (ja) | 交感神経刺激剤及びベーター1選択性ベータ遮断薬の組合せを含む抗緑内障組成物 | |
US5428030A (en) | Method of reducing elevated intraocular pressure | |
US4826812A (en) | Antiglaucoma agent | |
EP0375319A3 (en) | Angiotensin converting enzyme inhibitors in the treatment of glaucoma |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20040511 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20040804 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20040917 |
|
A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20041111 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20050823 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20050902 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |